| 2018-04-09 06:21:42|
RCUS 06:21 04/09 04/09/18
Arcus Biosciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Arcus Biosciences with a Buy rating and $25 price target. The analyst says that while lead compound data is not expected until the first half of 2019, Arcus' proven management and drugs targeting validated pathway make the company competitive despite the crowded landscape in solid tumors.